Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Rollins Q3 Likely 'Choppy' But Bounce Possible, UBS Says

Rollins Q3 Likely 'Choppy' But Bounce Possible, UBS Says

MT newswireMT newswire2026/10/14 18:47
02:47 PM EDT, 10/14/2026 (MT Newswires) -- Rollins (ROL) could see a short-term share bounce on Q3 results amid low expectations, UBS said in a note Wednesday. The Q3 results are due Oct. 21. "We expect a continued choppy Q3 from Rollins, but believe that buyside expectations are low enough that there could be a short-term bounce possible," the report said. The report said Q3 organic growth estimate was cut to 5.8% from 6.3%, broadly in line with consensus, though buyside expectations are closer to 5.3% to 5.5%. Fundamentally over the medium to longer-term, some conviction that Rollins is beginning to address the traffic flow issue will be needed, the report said. UBS lowered its price target to $36 from $43 while keeping a neutral rating. Price: 32.42, Change: +0.27, Percent Change: +0.82
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

No scientific evidence but viral on social media: “Bodybuilding miracle drug” peptide products deregulation file sent to the White House for review, Hims&Hers (HIMS.US) surged 6% in one day.

The temporary admission policy for peptides has been submitted to the White House for review, and compounding pharmacies are expected to receive approval to produce BPC-157 and other substances; HIMS closed up 6% on Thursday.

智通财经•2026/10/16 00:11